Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Raising of Funds
Pursuant to Regulation 30 of SEBI (LODR), 2015 WE wish to inform that the Board of Directors has considered and approved for issuance of equity shares to existing shareholders on Rights Basis Solara Active Pharma Sciences Ltd - 541540 - Board Meeting Outcome for Outcome Of Board Meeting
1. The offer and issuance of equity shares of face value of ?10 each of the Company (the "Equity Shares") for an aggregate amount, including premium, not exceeding Rs. 450 Crores (Rupees Four Hundred and Fifty Crores) by way of a rights issue to the eligible equity shareholders of the Company as on the record date (to be determined and notified subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, subject to such approvals, as may be required under the applicable laws ("Rights Issue"). Solara Active Pharma Sciences Ltd - 541540 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 (1) Of SEBI Listing Regulations
Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/07/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations''), this is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, July 5, 2023 inter alia to consider the proposal to issue equity shares to existing shareholders on Rights basis, as may be permitted under applicable law, subject to such regulatory/statutory approvals, as may be required. Solara Active Pharma Sciences Ltd - 541540 - Closure of Trading Window
In accordance with Company''s Code of Conduct for Prohibition of Insider Trading, the trading window for dealing in the securities of the company shall be closed for designated persons and their relatives with effect from Friday, June 30, 2023 , till 48 hours from the date of declaration of unaudited financial results of the company for the quarter ended June 30, 2023. Solara Active Pharma Sciences Ltd - 541540 - Announcement Under Regulation 30 - Significant Increase In Volume
We refer to your mail seeking clarification on the significant increase in volume in the securities of the Company across exchanges in the recent past. We wish to clarify that Company has made all the required disclosures pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and has not withheld any material information/event that, in our opinion, would have a bearing on the price/volume behaviour in the scrip. Solara Active Pharma Sciences Ltd - 541540 - Clarification sought from Solara Active Pharma Sciences Ltd
The Exchange has sought clarification from Solara Active Pharma Sciences Ltd on June 16, 2023, with reference to Movement in Volume.The reply is awaited.
Solara Active Pharma spurts 9% on heavy volumes
The stock saw a sharp upmove of 300 percent between March 2020 and July 2021, touching Rs 1,800 as COVID outbreak led to a spike in demand for its main offerings Ibuprofen, Favipiravir and Gabapentin Solara Active Pharma Sciences Ltd - 541540 - Statement On Deviation Or Variation Of Funds Raised Through Preferential Issue Of Convertible Warrants
With reference to the above, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated January 31, 2019. Solara Active Pharma Sciences Ltd - 541540 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In Compliance with Regulation 24 A of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation 2015, we are enclosing a copy of Annual Secretarial Compliance Report for the financial year 2022-23 issued by Mr. A. Mohan Kumar, Practicing Company Secretary. Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter ended March 31, 2023, conducted after the meeting of Board of Directors held on May 12, 2023, for your information and records.